Pfizer Inc’s vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit ... Read More
We use cookies to improve your browsing experience on our website. To find out more, please read our Privacy Policy and Cookies Policy, been updated and became effective May 24, 2018.
By continuing to navigate our website without changing your cookies settings, or by clicking 'Ok', you hereby acknowledge and agree to OneStopBrokers use of cookies.OkRead more